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ABSTRACT We report evidence that gene complexes,
consisting of polycations and plasmid DNA enter cells via
binding to membrane-associated proteoglycans. Treatment of
HeLa cells with sodium chlorate, a potent inhibitor of pro-
teoglycan sulfation, reduced luciferase expression by 69%o.
Cellular treatment with heparinase and chondroitinase ABC
inhibited expression by 78% and 20%0o with respect to control
cells. Transfection was dramatically inhibited by heparin and
heparan sulfate and to a smaller extent by chondroitan sulfate
B. Transfection of mutant, proteoglycan deficient Chinese
hamster ovary cells was 53 x lower than of wild-type cells. For
each of these assays, the intracellular uptake of DNA at 37°C
and the binding of DNA to the cell membrane at 4°C was
impaired. Preliminary transfection experiments conducted in
mutant and wild-type Chinese hamster ovary cells suggest
that transfection by some cationic lipids is also proteoglycan
dependent. The variable distribution of proteoglycans among
tissues may explain why some cell types are more susceptible
to transfection than others.
Because of the current interest in gene therapy, a number of
nonviral transfection agents have been developed. Among
them are polylysine- (PLL) and lipid-based amphiphiles, which
belong to a diverse class of macromolecules that form stable
complexes with DNA. At optimum formulations, these agents
surround DNA with a net positive charge, that in turn, enable
the DNA complex to bind to anionic residues on the cell
surface. Following entry into the cell by endocytosis, a fraction
of the DNA enters the nucleus and the gene of interest is
transcribed (1).
Despite the advances in this field, few studies have focused
on the molecular mechanisms of gene delivery. In particular,
the membrane molecules that are responsible for the trans-
fection of cation-DNA complexes have never been investi-
gated. Here, we report evidence that sulfated, membrane-
associated proteoglycans serve as a receptor for transfection by
PLL and possibly by some cationic lipids.
Sulfated proteoglycans are among the most negatively
charged components of the cell. They consist of a core protein
covalently linked to one or more sulfated glycosaminoglycans:
heparin, heparan sulfate, dermatan sulfate, chondroitan sul-
fate, and keratan sulfate (2, 3). Proteoglycan synthesis begins
in the endoplasmic reticulum with the formation of the protein
core (4, 5). As the protein core is transported from the rough
endoplasmic reticulum to the Golgi, serine residues are linked
to D-xylose by xylosyltransferase (6). The protein core is
further modified with two galactosyl residues and a glucurono-
syl residue. Starting from this sugar, the glycosaminoglycan
backbone is synthesized. Sulfates are transferred from aden-
osine 3'-phosphate 5'-phosphosulfate by sulfotransferase onto
the glycosaminoglycans (7). Finally, the glycosaminoglycan
residues are epimerized before the proteoglycans are exported
to their final destination (8, 9).
Proteoglycans are a fundamental component of basement
membranes (10) and the extracellular matrix, and play a pivotal
role in cellular proliferation, migration, and differentiation
(11, 12). As integral and glycosylphosphatidyl inositol-linked
membrane proteins, heparan sulfate and chondroitan sulfate
proteoglycans sequester protease inhibitors, growth factors,
and proteases and serve as a receptor for infection by the
herpes simplex virus (for reviews, see refs. 13 and 14).
Because glycosaminoglycans are highly anionic, the inter-
actions between proteoglycans and their ligands occur largely
through ionic forces. Based on this information, we proposed
that membrane-associated proteoglycans mediate the binding
and delivery of cation-DNA complexes into cells. To test this
hypothesis, a number of assays were used. Since proteoglycan
charge is derived mostly from the sulfation of the glycosami-
noglycan chains (2), transfection was assayed in HeLa cells
cultured in the presence of sodium chlorate, an inhibitor of
glycosaminoglycan sulfation (15). Transfection was also tested
in cells pretreated with glycosaminoglycan lyases to remove
extracellular glycosaminoglycans (16) and in the presence of
purified glycosaminoglycans. In addition, the transfection ef-
ficiency of PLL-and cationic lipid-DNA was tested in wild-type
Chinese hamster ovary (CHO) cells and in mutant CHO cells
unable to synthesize proteoglycans (17).
MATERIALS AND METHODS
Cell Culture. HeLa cells were obtained from the American
Type Culture Collection and grown in DMEM (GIBCO)
containing basal Eagle's medium amino acids (GIBCO), non-
essential amino acids (GIBCO), 10% fetal bovine serum
(HyClone), and 40 mg/ml gentamicin (GIBCO).
Mutant (CHO-pgs745) and wild-type (CHO-Kl) cells were
generously donated by Jeffrey Esko (University of Alabama
School of Medicine, Birmingham). The mutant cell line lacks
xylosyltransferase, an initiator of glycosaminoglycan synthesis.
Both cell lines were grown in Ham's F-12 medium, supple-
mented with 7.5% fetal bovine serum, and subcultured every
4 days.
Media for PLL transfections consisted of regular growth
media (DMEM/10% fetal bovine serum or Ham's F-12/7.5%
fetal bovine serum) supplemented with 100 ,uM chloroquine
(Sigma). Lipid-DNA transfections were carried out in wild-
type and mutant CHO cells in serum-free Ham's F-12 medium.
Experiments were conducted using subconfluent cultures.
Preparation of Complexes and Transfection. An aliquot of
poly-L-lysine (100 ,ug/ml, Sigma, molecular mass 56 kDa) was
added to DNA (1.5 ,ug/100 ,ug/ml) diluted in 150 liters
Hepes-buffered saline (50 mM Hepes/150 mM NaCl, pH 7.4).
PLL-DNA samples were mixed gently, incubated for 30 min at
room temperature, and added to cells in transfection media.
Four hours later, cells were rinsed twice in 1 ml PBS (8 mM
Na2HPO4/3 mM KCl/138 mM NaCl/2 mM KH2PO4, pH 7.4)
and placed into fresh culture media at 37°C. Following an
Abbreviations: CHO, Chinese hamster ovary; PPL, polylysine.
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additional 21 hr at 37°C, the medium was removed and cells
were rinsed twice with 2 ml PBS. Luciferase expression in
cellular lysates was determined using an Enhanced Luciferase
Assay kit (Analytical Luminescence Laboratory, San Diego)
according to the manufacturer's instructions. Expression was
quantitated in terms of relative light units on an Analytical
Luminescence Laboratory model 2010 Luminometer.
Preparation of Fluorescent and Nick-Translated Plasmids.
The PGL2 plasmid (Promega) encoding the firefly luciferase
reporter gene was amplified in competent JM109 Escherichia
coli (Promega) and purified by chromatographic methods
(Qiagen, Chatsworth, CA). Plasmid DNA was diluted to 100
,ug/ml in sterile, distilled water.
DNA (1.5 gg) was labeled with [a-32P]dCTP (3000 Ci/
mmol; 1 Ci = 37 GBq) using a nick translation kit (Boehringer
Mannheim) and purified by repeated chloroform/phenol ex-
tractions and ethanol precipitation (18). A stock solution of
DNA was prepared by mixing nick translated plasmid with =30
,tg unlabeled plasmid. The concentration of DNA was deter-
mined by absorbance (,\m.a = 260 nm).
To prepare fluorescent DNA, plasmid (100 ,ug/ml) was
incubated with a 50-fold molar excess of YOYO-1 (Molecular
Probes) and a fluorescent DNA intercalator (19, 20) for 2 hr
at 4°C. The solution was loaded onto a Centricon-30 desalting
unit and spun for 3 hr at 6000 rpm at 4°C to remove unbound
YOYO. The retentate was diluted to its original concentration
in sterile water. The concentration ofYOYO per mole plasmid
was determined by spectrophotometric analysis. The fluores-
cence of YOYO-DNA (YYDNA) was measured (Aex = 488
nm, Aem= 512) in a Hitachi model F-4500 fluorescence spec-
trophotometer.
Desulfation of Cells. HeLa cells (2 x 104 cells per ml) were
seeded into 12-well plates (Falcon). Twelve hours later, media
were supplemented with sodium chlorate (35 mM, Aldrich) or
a combination of sodium sulfate (80 mM, Baker) and sodium
chlorate (35 mM). Following an additional 48-hr incubation
period, cells were rinsed twice with 1 ml PBS and placed into
1 ml transfection media. Transfection, uptake, or binding
experiments immediately followed. The transfection was con-
ducted in the absence of chlorate to minimize the possible
effects that this compound might have on cellular processes
unrelated to proteoglycans.
Treatment of Cells with Glycosaminoglycan Lyases and
Purified Glycosaminoglycans. HeLa cells were seeded (5 x
104 cells per ml) into 12-well plates (Falcon). Eighteen hours
later, cells were rinsed twice with 1 ml PBS and placed into a
BSA/PBS solution containing either 10 units/ml chondroiti-
nase ABC (Sigma) or 10 units/ml heparinase II (Sigma) (16).
Cells were incubated with lyases for 1 hr at 22°C. Following the
removal of surface glycosaminoglycans, cells were rinsed twice
with PBS and transfected according to the usual protocol.
Glycosaminoglycans (chondroitan sulfate A, bovine trachea;
chondroitan sulfate B, bovine mucosa; chondroitan sulfate C,
shark cartilage; heparan sulfate, bovine trachea; heparin,
bovine trachea; hyaluronic acid, bovine mucosa) were pur-
chased from Sigma. To evaluate the effect of free glycosami-
noglycans on transfection, DNA complexes and glycosamino-
glycans (40 g/ml heparan sulfate, heparin, chondroitan sulfate
A, chondroitan sulfate B, chondroitan sulfate C, or hyaluronic
acid) were added together at the time of transfection. Trans-
fected cells were treated according to the usual protocol.
Fluorescence Uptake Experiments and Confocal Micros-
copy. HeLa, CHO-pgs745, and CHO-Kl cells were incubated
with PLL-YYDNA for 4 hr and then rinsed three times in PBS.
To remove surface bound DNA, cells were treated with DNase
(1 mg/ml, Sigma) for 15 min and then detached with trypsin-
EDTA. Cell suspensions were pelleted, washed twice in PBS,
and fixed in 4% paraformaldehyde/PBS for 10 min at room
temperature. After a final rinse in PBS, cell pellets were
resuspended in Biomeda/PBS solution (90:10) and mounted
between a slide and coverslip. Fluorescence images were
obtained using a Bio-Rad confocal microscope.
Binding Assays. Complexes were prepared as described
using nick-translated plasmid and then added to cells that were
prechilled to 4°C. After a 2-4 hr incubation at this tempera-
ture, cells were rinsed four times in ice-cold PBS and detached
with trypsin-EDTA. Aliquots were dissolved in Safety Solve
scintillation cocktail, radioactivity (counts per min) was quan-
titated in a Beckman model LS 5000 TD scintillation counter.
Cellular protein was determined by the fluoraldehyde assay
(Pierce).
RESULTS
PLL-Mediated Transfection Requires Positively Charged
Complexes. The net charge on a DNA complex can signifi-
cantly influence transfection efficiency. Optimum formula-
tions with cationic lipids consist of a molar excess of positive
charge (1). To determine the optimum charge ratio for PLL,
a series of complexes prepared with 1.5 ,ug DNA and varying
amounts of PLL were transfected into HeLa cells.
Complexes composed of amine/nucleotide charge ratios < 1
yielded very little expression (Fig. 1). Expression increased
nonlinearly with PLL concentration and reached a peak (5 x
105 relative light unit/mg cell protein) at a charge ratio
(amine/nucleotide) equal to 1.5. Agarose gel electrophoresis
confirmed that complexes composed of this ratio were posi-
tively charged (data not shown). Cellular uptake assays re-
vealed that this ratio was optimal for cellular uptake of
nick-translated and fluorescently labeled DNA. Complexes
with ratios larger than 1.5 yielded lower expression values
according to previous observations (21). These results are
consistent with the putative ionic model to describe the
interactions between the cell membrane and cation-DNA
complexes.
Sulfates Mediate PLL-DNA Transfection. The role of pro-
teoglycans in cellular processes has been demonstrated by
inhibiting glycosaminoglycan sulfation with sodium chlorate
(22, 23). Chlorate is a nontoxic inhibitor of ATP-sulfurylase,
an essential enzyme in the synthesis of 3'-phosphoadenosyl-
5'-phosphosulfate, a glycosaminoglycan sulfate donor (15, 24).
To test the role of sulfated proteoglycans in transfection,
cells were grown in the presence of sodium chlorate for 48 hr
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FIG. 1. Determination of the optimum charge ratio (lysine/
nucleotide) for the transfection of PLL-DNA. Varying amounts of
PLL (100 ,ug/ml) were added to 1.5 ,ug plasmid DNA diluted in 150
,ul Hepes-buffered saline. Samples were gently agitated, equilibrated
for 30 min, and added to HeLa cells in transfection media. Following
a 4-hr incubation at 37°C, transfection medium was removed, and cells
were washed twice in 2 ml PBS. Cells were grown for an additional 21
hr in fresh growth media and then washed in PBS. Luciferase
expression in cellular lysates was determined using an Enhanced
Luciferase Assay kit and a Monolight Luminometer (Analytical Lu-
minescence Laboratory) according to the manufacturer's instructions.
Results obtained from different charge ratios are presented as a
percent of the maximum observed expression.
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FIG. 2. Effect of sodium chlorate concentration on transfection. HeLa cells were grown for 48 hr in the presence of varying amounts of sodium
chlorate or were left untreated as a control. (A) Cells were transfected as described (Fig. 1) using PLL-DNA complexes made with the optimum
charge ratio. (B) Complexes composed of YOYO-labeled DNA (YYDNA) and PLL were prepared and incubated with chlorate treated (35 mM)
and untreated HeLa cells at 37°C. After 4 hr, cells were rinsed extensively and incubated in 1 ml PBS/deoxyribonuclease (Sigma, 50 ,tg/ml) for
15 min. Cells were trypsinized, fixed in 4% paraformaldehyde, and suspended in Biomeda/PBS (90:10) solution. Cells were mounted onto a glass
slide and coverslip and imaged 12 hr later using a Bio-Rad Confocal microscope. Each panel contains approximately the same number of cells.
(C) HeLa cells were treated with sodium chlorate (35 mM) or with sodium chlorate (35 mM) and sodium sulfate (80 mM) for 48 hr or with sodium
chlorate (35 mM) for 4 hr. Then, PLL-32PDNA complexes were prepared and incubated with cells for 4 hr at 4°C to inhibit endocytosis. Cells were
rinsed extensively in ice cold PBS and dissolved in 1.0 M NaOH. Aliquots of dissolved cells were added to 10 ml Scintillation fluid and counted
for one minute in a Beckman model 2010 scintillation counter. Samples were assayed in duplicate and normalized per mg cell protein. Error bars
represent the actual data points of duplicate samples.
and transfected with PLL-DNA. As demonstrated by Fig. 2A,
expression was inhibited by chlorate in a concentration de-
pendent manner. At 35 mM chlorate, luciferase expression was
30% relative to untreated cells. The inhibition of gene expres-
sion was probably not caused by chlorate toxicity, because
cellular morphology and proliferation remained normal at all
chlorate concentrations.
However, these results could possibly be due to intracellular
artifacts unrelated to the delivery mechanism ofPLL-DNA. To
elucidate the effects of chlorate more clearly, we tested
whether chlorate treatment inhibited the uptake of DNA into
the cell. DNA was labeled with YOYO, a fluorescent inter-
calator, complexed with PLL at the optimum ratio, and
incubated with chlorate treated (35 mM) and untreated HeLa
cells. After 4 hr, cells were washed, fixed, and imaged by
confocal microscopy to localize intracellular fluorescence. As
shown in Fig. 2B uptake ofYYDNA into chlorate-treated cells
was severely impaired suggesting that the chlorate induced
decrease in expression was due to an inhibition of YYDNA
entering the cell.
To demonstrate a direct correlation between the uptake of
PLL-DNA and sulfated cell membrane residues, we tested
whether chlorate treatment inhibited binding of DNA to the
cell surface. Complexes ofPLL and nick translated 32P-labeled
plasmid were prepared and incubated with HeLa cells, previ-
ously treated with chlorate, for 4 hr at 4°C to inhibit endocy-
tosis. Cells were washed extensively with ice-cold PBS, dis-
solved, and assayed for cell-associated radioactivity. As shown
in Fig. 2C, binding of PLL-32P-DNA to chlorate treated cells
was inhibited 69% with respect to untreated cells. In HeLa
cells cotreated with chlorate and excess sulfate, the inhibitory
effect of chlorate was reversed. Furthermore, HeLa cells
incubated with chlorate for only 4 hr bound as much PLL-
32P-DNA as untreated cells. We conclude that chlorate inhibits
luciferase expression by inhibiting the sulfated receptors,
possibly proteoglycans, that mediate transfection. Additional
evidence was sought to implicate proteoglycans directly.
Effect of Exogenous Glycosaminoglycans and Glycosami-
noglycan Lyases on Transfection of PLL-DNA. To test if
glycosaminoglycans could competitively inhibit gene delivery,
HeLa cells were cotransfected in the presence of exogenous
glycosaminoglycans (40 ,ug/ml). Following exposure to DNA
complexes and glycosaminoglycans, cells were washed, incu-
bated in fresh culture medium, and assayed for luciferase
expression 22 hr later (Fig. 3A). The most anionic glycosami-
noglycans, heparin and heparan sulfate, nearly eliminated
luciferase expression, whereas chondroitans A and C and
hyaluronic acid had no effect. Chondroitan sulfate B, the third
most anionic glycosaminoglycan, reduced expression by
-40%.
Since excess glycosaminoglycans in media have been shown
to affect DNA transcription (25), we tested whether the
intracellular uptake of YYDNA was affected by exogenous
glycosaminoglycans. PLL-YYDNA complexes and glycosami-
noglycans were incubated with HeLa cells for 4 hr at 37°C.
Cells were rinsed, fixed, and mounted onto glass slides. Con-
focal microscopy images of intracellular fluorescence (Fig. 3B)
revealed a correlation between expression and YYDNA up-
take in the presence of competing glycosaminoglycans. Hep-
arin and heparan sulfate eliminated the uptake of YYDNA
into the cells, but chondroitan sulfates A and C did not have
any obvious effect. Chondroitan sulfate B moderately reduced
the uptake ofYYDNA into the cell. Binding of32P-DNA to the
cell surface was tested in the presence of-glycosaminoglycans
and a similar pattern of inhibition was observed (data not
shown).
It could be argued that any highly sulfated, anionic polymer
in the media could inhibit transfection by destabilizing the
interactions between PLL and DNA. Indeed, when dextran
sulfate, a synthetic glycosaminoglycan analog, was added to the
media, reductions in uptake and expression comparable to
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FIG. 3. Effect of exogenous glycosaminoglycans on transfection.
(A) HeLa cells were transfected with PLL-DNA in the presence of
purified glycosaminoglycans (40 ,tg/ml). Results are presented as a
percentage of luciferase expression relative to cells transfected in the
absence of glycosaminoglycans. Error bars represent the actual data
points of duplicate samples. Lanes: 1, chondroitan sulfate A; 2,
chondroitan sulfate B; 3, chondroitan sulfate C; 4, hyaluronic acid; 5,
heparin; 6, heparan sulfate. (B) HeLa cells were transfected with
PLL-YYDNA in the presence of purified glycosaminoglycans (40
,tg/ml). Cells were prepared and imaged as described (Fig. 2C). Lanes:
1, control; 2, chondroitan sulfate A; 3, chondroitan sulfate B; 4,
chondroitan sulfate C; 5, heparin; 6, heparan sulfate. Each panel
contains approximately the same number of cells.
those induced by heparin were observed (data not shown). As
an additional control, HeLa cells were transfected following
treatment with glycosaminoglycan lyases. By removing hepa-
rin/heparan sulfate and chondroitan sulfates with heparinase
II and chondroitinase ABC, expression was reduced by 78%
and 20%, respectively (Fig. 4). Moreover, treatment of cells
with hyaluronase that removes nonsulfated hyaluronic acid
glycosaminoglycans found in the extracellular matrix did not
inhibit luciferase expression. These results suggest that hepa-
rin/heparan sulfate proteoglycans and, to a smaller extent,
chondroitan sulfate B proteoglycans are mediators of trans-
fection by PLL-DNA.
Cells Lacking Proteoglycans Are Transfection Deficient. To
demonstrate that proteoglycans play a role in gene delivery
into other cell lines, transfection efficiency was tested in
wild-type CHO-Ki cells and in mutant CHO-pgs745 cells
deficient in xylosyltransferase, an essential enzyme in proteo-
glycan synthesis. Despite their inability to produce proteogly-
FIG. 4. Transfection of cells treated with glycosaminoglycan lyases.
To test the effect of lyases on transfection, cells were incubated in the
presence of either chondroitinase ABC or heparinase for 1.5 hr and
transfected according to methods described in Fig. 1. Error bars
represent the actual data points over duplicate samples.
cans, CHO-pgs745 cells are highly proliferative and are mor-
phologically indistinct from their wild-type counterparts (17).
Both CHO-Kl and CHO-pgs745 cells were transfected with
the same amount of DNA and with the same charge ratio, but
luciferase expression in proteoglycan-deficient cells was 53x
lower than in wild-type cultures (Fig. 5A). Consistent with
previous observations, the uptake ofPLL-YYDNA into CHO-
pgs745 cells was dramatically lower than into CHO-Kl cells
(Fig. SB), and the binding of PLL-32P-DNA to CHO-pgs745
cells was inhibited 80% with respect to wild-type CHO cells
(data not shown).
Role of Proteoglycans in Cationic Lipid-Mediated Trans-
fection. The experiments described support the hypothesis that
membrane-associated proteoglycans mediate the delivery of
PLL-DNA. In practice, unmodified PLL is not a widely used
agent for transfection, because the transfection efficiency is
low compared with cationic lipids. To evaluate the role of
proteoglycans in a more common transfection system, the
transfection efficiency of a series of cationic lipids (PerFect
Transfection kit, Invitrogen) was tested in wild-type and
mutant CHO cells. The formulations tested were either a
mixture of two cationic lipids (pfx-1), a 1:1 mixture of dio-
leoylphosphatidylethanolamine (DOPE)/cationic lipid (pfx-6
and pfx-7), or a single cationic lipid (pfx-8).
Each formulation was transfected into CHO-Kl and CHO-
pgs745 cells (-2 x 105 cells per well) using 4 jig DNA and the
optimum amount of lipid (as determined by the manufacturer).
Cells were exposed to lipid-DNA complexes for 4 hr in
serum-free Ham's F-12 media, rinsed twice with PBS, and
incubated in regular growth media. Twenty hours later, a
significant number of dead cells and cellular debris was
observed especially in cultures transfected with pfx-7 and pfx-8.
Cationic liposome induced toxicity has been observed previ-
ously, although the reasons for this toxicity are unclear.
To eliminate the possible artifacts that might arise from
toxicity, cells were transfected again with a 20-fold lower
concentration of lipid-DNA. At these concentrations, very few
dead cells were observed in any of the cultures. Following the
transfection, all cultures were rinsed and assayed for luciferase
activity.
A correlation quotient, X, defined as (relative light units in
wild-type cells/relative light units in mutant cells) was plotted
for each type of lipid (Fig. 6). For pfx-1 formulations, X was
equal to 81, indicating that wild-type cells expressed 81 x more
luciferase than proteoglycan deficient cells. The correlation
quotient determined for the other lipid formulations was 10.7,
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FIG. 5. Transfection of wild-type and mutant CHO cells by PLL.
(A) PLL-DNA complexes were transfected into wild-type and mutant
CHO cells according to the methods described in Fig. 1. (B) Cells were
prepared and imaged as described (Fig. 2B). Each panel contains
approximately the same number of cells.
1.7, 4.8, and 1.7 for pfx-4, pfx-6, pfx-7, and pfx-8, respectively.
The highest levels of raw luciferase expression in both CHO
cell lines were obtained with pfx-1-DNA and pfx-4-DNA and
the lowest levels from pfx-6, pfx-7, and pfx-8-DNA.
DISCUSSION
In this paper, we investigated the identity of the anionic mem-
brane sites that mediate transfection by PLL. Because proteo-
glycans bind and internalize a wide range of cationic substrates in
the body, we hypothesized that gene delivery is mediated by
proteoglycans bound to the cell surface. Transfection was tested
in cells treated with chlorate to evaluate the role of sulfated
proteoglycans in the transfection mechanism. Chlorate dimin-
ished binding of PLL-DNA to the cell surface at 4°C, which
suggested that the first step in the transfection process involved
binding to sulfated proteoglycans. Chlorate treatment also di-
minished the uptake of DNA as well as the expression of the
luciferase reporter gene. Taken together, these results indicate
that DNA complexes are effectively bound and internalized by
membrane-associated proteoglycans.
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FIG. 6. Transfection of wild-type and mutant CHO cells by cationic
lipids. An optimum amount of each type of lipid was used to transfect
CHO-Ki and CHO-pgs745 cells (-2 x 105 cells per well) with 0.2 ,ug
DNA. Cells were exposed to lipid-DNA complexes for 4 hr in
serum-free Ham's F-12 media, rinsed twice with PBS, and incubated
in regular growth media for an addition 20 hr. Luciferase expression
in cellular lysates was determined as described (Fig. 1).
We also demonstrated that exogenous heparin and heparan
sulfate preferentially inhibited transfection, probably by bind-
ing and destabilizing complexes in solution and preventing
intact complexes from entering the cell. These results do not
directly support a role for membrane-associated proteoglycans
in transfection but explain why heparin is a serious inhibitor of
transfection and also support the results of recently published
work in this area (26). Since the least anionic glycosamino-
glycans, the chondroitan sulfates, had very little effect on
transfection and dextran sulfate, an anionic glycosaminoglycan
analog, dramatically inhibited transfection, the inhibition by
heparin and heparan sulfate proteoglycans is probably a non-
specific effect, dependent on charge effects rather than on
structural features.
However, direct evidence was found to implicate mem-
brane-associated heparin/heparan sulfate proteoglycans in
transfection. Treatment of cells with heparinase was an effec-
tive transfection inhibitor. Thus, PLL-DNA complexes may
preferentially transfect cells via heparin/heparan sulfate pro-
teoglycans. By showing that binding, uptake, and expression of
PLL-DNA was reduced in proteoglycan deficient cells relative
to wild-type cells, we confirmed that proteoglycans participate
in PLL-mediated gene delivery into other cell lines as well.
It is unclear whether the transfection inefficiency of CHO-
pgs745 cells is due solely to inefficient binding and transport of
PLL-DNA. In CHO-pgs745 cells, cellular binding of PLL-
32PDNA at 4°C was 5-fold lower than binding to wild-type cells,
but expression was inhibited 50-fold. To account for this
difference, it is possible that CHO-pgs745 cells possess other
intracellular deficiencies that can affect the expression of the
reporter gene. Alternatively, in the absence of proteoglycans
PLL-DNA may still bind to other anionic sites but may not
enter the cell efficiently. The lack of DNA uptake into
CHO-pgs745 cells is consistent with this hypothesis. Regardless
of whether proteoglycans are the sole membrane binding sites
for transfection, we conclude that a correlation exists between
membrane-associated proteoglycans and the efficiency of
PLL-mediated transfection.
Since PLL is not a widely used transfection agent, prelim-
inary experiments were conducted to evaluate the possible role
of proteoglycans in the transfection by cationic lipids. Lucif-
erase expression in wild-type cultures relative to proteoglycan
deficient cells varied depending on the lipid. The strongest
correlation between transfection and proteoglycans, as well as
the highest expression levels, were obtained with pfx-1 and
pfx-4 lipids that consist of a mixture of two cationic lipids. The
Cell Biology: Mislick and Baldeschwieler
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weakest correlation and the lowest expression levels were
obtained with lipid formulations consisting of a 1:1 mixture of
a cationic lipid and DOPE or a single cationic lipid. Experi-
ments were not conducted to verify that the inhibition of
expression was directly caused by decreased binding and
uptake of lipid-DNA, but they are currently in progress. These
preliminary results are consistent with the hypothesis that
proteoglycans participate in the transfection of certain cationic
lipids, but we cannot conclude yet that other mechanisms do
not play an important role. Future studies will be conducted to
test the role of proteoglycans in the transfection by cationic
lipids of known structure so that a correlation between pro-
teoglycan-mediated transfection and precise structural fea-
tures can be elucidated.
In conclusion, we suggest that the variable expression of
proteoglycans among tissues may explain why some cell types
are more susceptible to transfection than others. Although all
tissues express proteoglycans to some level (27), proteoglycan
expression is regulated by both the state of differentiation and
growth of the cell. Immature myeloid and lymphoid cells
express the hematopoietic proteoglycan core protein (HpPG)
at low levels only but up-regulate the HpPG gene 10-fold upon
differentiation (28). Recently, the undifferentiated erythro-
leukemia cell line, K562, was shown to express 2-3 times more
of the basement membrane proteoglycan, perlecan, if the cells
were artificially stimulated to differentiate with 12-0-
tetradecanoylphorbol-13-acetate, a phorbol diester (29). Inci-
dentally, K562 cells are one of the most difficult cell lines to
transfect by cationic methods but yield high levels of expres-
sion by transferrin-PLL transfection (30). This implies that the
susceptibility of a cell type to transfection may partially depend
on the mechanism of entry and not entirely on intracellular
factors. The development of methods to increase expression in
these hematopoietic cell lines is important for ex vivo appli-
cations of gene replacement therapy. Experiments that at-
tempt to modulate proteoglycan expression as a means to
increase transfection by cationic methods are currently in
progress.
Finally, these experiments bring to light the possible barriers
that might be encountered by gene delivery in vivo. The
inhibition of transfection by heparin and other charged com-
ponents in serum has been established (31). This problem is
avoided in vitro by conducting transfection experiments in
serum-free media. Although typical concentrations of heparin
in blood are low, the presence of heparin combined with other
charged serum components might seriously affect transfection
in vivo. Gene delivery might also be inhibited by wasteful
binding of DNA complexes to the extracellular matrix and to
basement membranes of tissues in the body. If these problems
prove to be significant in vivo, then alternative gene delivery
vectors that are are optimized at more neutral charge ratios
may have to be developed.
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